TY - JOUR
T1 - Combined targeted therapy and immunotherapy in melanoma
T2 - a review of the impact on the tumor microenvironment and outcomes of early clinical trials
AU - Pelster, Meredith S.
AU - Amaria, Rodabe N.
N1 - Funding Information:
RA receives research funding from Merck, Bristol Myers-Squibb, Array Biopharma, Genentech and Iovance Biotherapeutics.
Publisher Copyright:
© The Author(s), 2019.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint inhibitors have changed the management of advanced stage melanoma and improved the outcomes of patients with this malignancy. However, both therapeutic approaches have limitations, including a limited duration of benefit in subsets of BRAF-mutant melanoma patients treated with targeted therapy and a lower overall response rate without a clear predictive biomarker in patients treated with checkpoint inhibitors. Preclinical and translational data have shown that BRAFis and MEKis alter the tumor microenvironment to make it more amenable to immunotherapy and have provided the scientific rationale for combing BRAFis and MEKis with immunotherapy. In this review, the initial studies demonstrating the impact of BRAFis and MEKis on the expression of melanoma differentiation antigens, T-cell infiltration, and the balance of immune stimulatory and immune suppressive cells and cytokines are addressed. Preclinical work on the combination of targeted therapy with BRAFis and MEKis with immunotherapy are reviewed, highlighting improved tumor responses in mouse models of BRAF-mutated melanoma treated with combinatorial strategies. Lastly, data from early clinical trials of combined targeted therapy and immunotherapy are discussed, focusing on response rates and toxicities.
AB - The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint inhibitors have changed the management of advanced stage melanoma and improved the outcomes of patients with this malignancy. However, both therapeutic approaches have limitations, including a limited duration of benefit in subsets of BRAF-mutant melanoma patients treated with targeted therapy and a lower overall response rate without a clear predictive biomarker in patients treated with checkpoint inhibitors. Preclinical and translational data have shown that BRAFis and MEKis alter the tumor microenvironment to make it more amenable to immunotherapy and have provided the scientific rationale for combing BRAFis and MEKis with immunotherapy. In this review, the initial studies demonstrating the impact of BRAFis and MEKis on the expression of melanoma differentiation antigens, T-cell infiltration, and the balance of immune stimulatory and immune suppressive cells and cytokines are addressed. Preclinical work on the combination of targeted therapy with BRAFis and MEKis with immunotherapy are reviewed, highlighting improved tumor responses in mouse models of BRAF-mutated melanoma treated with combinatorial strategies. Lastly, data from early clinical trials of combined targeted therapy and immunotherapy are discussed, focusing on response rates and toxicities.
KW - BRAF inhibitor
KW - MEK inhibitor
KW - immunotherapy
KW - melanoma
KW - targeted therapy
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85061914773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061914773&partnerID=8YFLogxK
U2 - 10.1177/1758835919830826
DO - 10.1177/1758835919830826
M3 - Review article
C2 - 30815041
AN - SCOPUS:85061914773
SN - 1758-8340
VL - 11
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -